Skip to Content
Merck
CN

S6826

Sigma-Aldrich

Stiripentol

≥98% (HPLC), Anti-convulsant reagent, powder

Synonym(s):

4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol, Diacomit

Sign Into View Organizational & Contract Pricing

About This Item

Empirical Formula (Hill Notation):
C14H18O3
CAS Number:
49763-96-4
Molecular Weight:
234.29
EC Number:
256-480-9
MDL number:
MFCD00869310
UNSPSC Code:
12352200
PubChem Substance ID:
329824570
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Stiripentol, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: ≥20 mg/mL

storage temp.

−20°C

SMILES string

CC(C)(C)C(O)\C=C\c1ccc2OCOc2c1

InChI

1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+

InChI key

IBLNKMRFIPWSOY-FNORWQNLSA-N

Application

Stiripentol has been used in pharmacokinetic analysis and as a reference standard in fluorescence spectra analysis.
Stiripentol may be used in GABAA receptor-mediated cell signaling studies.

Biochem/physiol Actions

Anti-convulsant drug

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000470185
0000470181
0000470185
0000470181
0000468836

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Catherine Chiron
Developmental medicine and child neurology, 53 Suppl 2, 16-18 (2011-04-29)
Dravet syndrome is a highly pharmaco-resistant form of epilepsy. Valproate and benzodiazepines are the first-line treatment but are usually insufficient therapeutic options. Lamotrigine, carbamazepine and high doses of intravenous phenobarbital can aggravate seizures and should be avoided. Topiramate, levetiracetam, bromide
Atsushi Fujiwara et al.
Journal of anesthesia, 34(3), 373-381 (2020-03-20)
Antiepileptic drugs are used not only for the treatment of epilepsy but also for that of neuropathic pain. However, their action mechanisms have not always been well explained. Stiripentol, an effective antiepileptic drug indicated as a therapeutic for Dravet syndrome
Janet L Fisher
European journal of pharmacology, 654(2), 160-165 (2011-01-18)
Many patients with refractory epilepsy are treated with polytherapy, and nearly 15% of epilepsy patients receive two or more anti-convulsant agents. The anti-convulsant stiripentol is used as an add-on treatment for the childhood epilepsy syndrome known as severe myoclonic epilepsy
Stéphane Auvin et al.
Epilepsia, 54(12), 2082-2090 (2013-10-15)
After the first positive experimental data in rodents in the early 1970s demonstrating the anticonvulsant effect of stiripentol (STP), in vitro studies showed that STP acts directly on γ-aminobutyric acid A (GABAA ) receptors. Chloride influx is higher when these
Dana Merdariu et al.
Brain & development, 35(2), 177-180 (2012-04-24)
The syndrome of malignant migrating partial seizures of infancy (MMPSI) is characterized by early onset of multiple seizure types and overall poor prognosis. Seizures are markedly drug resistant and few reports have suggested the efficacy of some antiepileptic drugs. We
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service